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We have examined P-glycoprotein (P-gp) expression and function in cultured rat hepatocytes in response to dexamethasone (DEX), which is known 
to modulate various liver functions. Northern blot analyses revealed high levels of P-gp mRNAs in cultured untreated liver cells m comparison 
to those found in freshly isolated hepatocytes, while DEX-treated hepatocytes also displayed elevated, although weaker, P-gp levels. Similarly, 
Western blotting analysis indicated high levels of P-gp in liver cells maintained in the absence of DEX. The use of mdr gene-specific probes allowed 
us to show that DEX-modulated P-gp mduction in cultured hepatocytes involved mostly. if not specifically, mdrl gene regulation. Doxorubicin 
P-gp-mediated efllux analyses revealed lower intracellular doxorubicin accumulation m DEX-untreated liver cells than in DEX-treated ceils, thus 
indicating that over-expressed P-gp was functional. These data clearly show that DEX treatment strongly modulates P-gp expression in primary 
rat hepatocyte cultures through a specific effect on the mdrl gene. 
P-Glycoprotein; mdr gene; Rat hepatocyte; Dexamethasone; Doxorubicm: Primary culture 
1. INTRODUCTION 
The multidrug resistance (MDR) phenotype is usu- 
ally linked to over-expression of a plasma transmem- 
brane phosphoglycoprotein termed P-glycoprotein (P- 
gp) [l-3]. P-gp is thought to act as an ATP-dependent 
efflux pump and thus confers resistance to various 
structurally and functionally unrelated cytotoxic drugs. 
P-gp is encoded by mdr genes which constitute a small 
gene family comprising two members in humans 
(MDRl and MDR2) and three members in rodents 
(mdrl, mdr2 and mdr3) [4]. Only MDRl in humans and 
mdrl and mdr3 (also known as mdrlb and mdrla, re- 
spectively) in rodents have been demonstrated to be 
involved in drug resistance by transfection experiments 
VI. 
P-gp is abundant in many drug-resistant human tu- 
mors [6,7] and, in addition, is expressed in several nor- 
mal tissues, including the small intestine, kidney, and 
liver [S]. P-gp physiological function and regulation re- 
main unclear. In normal hepatocytes, P-gp expression 
appears to be induced after protein synthesis inhibition, 
thus suggesting a negative regulation by a labile protein 
factor [9,10]; it is also increased after partial hepatec- 
tomy or xenobiotic treatment [11,12]. Similarly, it is 
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strongly augmented in normal kidney cell lines after 
acute exposure to cytotoxic drugs [13]. Several studies 
are in favor of a link with steroids. P-gp localization in 
the adrenal cortex, in the trophoblast of the human 
placenta, and in the gravid uterus, suggests that steroid 
hormones could be endogenous substrates. Moreover, 
P-gp expression is modulated by estrogen and proges- 
terone in the secretory epithelium of the mouse uterus 
[14] and in rat pituitary cells [15]. Since various liver 
functions have been demonstrated to be strongly modu- 
lated both in vivo and in vitro by corticosteroid 
hormones [ 161, and since primary cultures of rat hepato- 
cytes represent a suitable model to analyze P-gp regula- 
tion in non-tumoral cells [17], we decided to investigate 
P-gp regulation in response to dexamethasone (DEX) 
treatment in this in vitro model. 
2. MATERIALS AND METHODS 
2.1. Chemicals 
Doxorubicm hydrochloride was purchased from Roger Bellon lab- 
oratories (Neuilly, France). Verapamil and DEX were obtained from 
Sigma Chemical Co. (St. Louis. MO). 
2.2. Cell isolation and culture 
Hepatocytes from adult male Sprague-Dawley rats weighing 180- 
200 g were isolated by perfusion of the liver with a collagenase solution 
as previously described [18]. They were seeded at a density of lo5 
cells/cm’ on plastic dishes in a medium consisting of 75% mmimal 
essential medium and 25% medium 199, supplemented with 0.2 mg/ml 
bovine serum albumin, 10 mg/ml bovine insulin and 10% fetal calf 
serum. 4 h after cell seeding the medium was discarded and cultured 
hepatocytes were then maintamed in serum-free medium in the ab- 
sence or presence of various concentrations of DEX. 
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Fig. I. Effect of dexamethasone (DEX) treatment on P-glycoprotein 
(P-gp) mRNA levels in cultured rat hepatocytes. Each well contams 
10 pug total RNAs prepared from freshly Isolated hepatocytes (FIH), 
hepatocytes cultured with or without DEX (IO-’ M) and harvested 1 
day (dl) or 2 days (d2) after cell seeding, or from multidrug-resistant 
rat hepatoma cells (RHC). RNAs were transferred to Hybond-N 
sheets after electrophoresis and hybridized with pCHP1 probe (A), 
which recognizes highly conserved regions of mdr genes, and with 
mdrl (B) and mdr3 (C) gene-specific probes. Transcript sizes (m kb) 
were estimated relative to the migration of 18 S and 28 S rRNA. 
2.3 Isolutwn of‘ RNA und blot analysrs 
Total RNA was extracted from cultured hepatocytes by the gua- 
mdium thiocyanate/cesium chloride method of Chirgwin et al. [19] as 
modttied by Raymondjean et al. [20]. For Northern blotting. 1Opg of 
total RNAs were subjected to electrophoresis m a denaturmg formal- 
dehyde/agarose gel and transferred onto Hybond-N sheets. RNA 
amount in each lane and transfer efficiency were verified by staimng 
the gel with ethidium bromide. The sheets were prehybridtzed and 
hybridtzed with “P-labeled probes. P-gp mRNAs were detected with 
a hamster pCHP1 probe [21] obtamed from the American Type Cul- 
ture Collection (Rockville, MD) and mouse mdrl BBpG4, mdr2 
HIpG3 and mdr3 H3pG3 probes (a generous gift from Dr. P Gras, 
McGill University. Montreal, Canada). The pCHP1 sequence has 
been shown to recognize highly conserved regions of mdr genes [22]. 
while BBpG4. HIpG3 and H3pG3 are mdrl-. mdr2- and mdr3-specific 
probes. respectively [23]. Glutathione-S-transferase 7-7 (GST7-7). al- 
bumin and glyceraldehyde phosphate dehydrogenase (GAPDH) 
mRNAs were analysed wtth rat GST7-7 pGSTr7 [24], albumin cDNA 
[25] and GAPDH cDNA [26] probes, respecttvely. After hybridiza- 
tion, the sheets were washed, dried and autoradiographed at *8O”C 
Total RNAs extracted from rat hepatoma cells isolated m our lab- 
oratory and displaymg a MDR phenotype associated with over-ex- 
pression of mdrl and mdr3 genes (Fardel et al., unpubhshed results) 
were used as positive controls for P-gp expression. 
2.4. Prcparatron of nwnhmne.~ arrd rmmu~~ohlottm~ 
Crude membranes were prepared from cultured hepatocytes by 
differential centrifugation as described by Germann et al. [27]. Mem- 
brane protems were separated on a SDS-7% polyacrylamide gel and 
electrophorettcally transferred to mtrocellulose sheets, Nitrocellulose 
sheets were blocked for 2 h with Tris-buffered salme containing 3% 
bovine serum albumm and sequentially Incubated with C219 monoclo- 
nal antibody (Centocor Inc.. Malvern. PA) raised agamst P-gp [28] 
and [“‘llprotein A (Amersham. Bucks, UK) After washing. blots 
were dried and autoradtographed at -80°C. A control blot was per- 
formed usmg the same protocol with non-immune myeloma cell as- 
cites as the primary antibody. 
2.5. Evaluatwn of‘mtracellular do.uoruhtctn concentrutton 
The intracellular concentration of doxorubicm was estimated as 
described by Schott et al. [29] with slight modifications. Cultured 
hepatocytes were exposed to doxorubicin (10 &ml) for 2 h and then 
washed with phosphate buffer. harvested and ultrasonicated. These 
steps were performed quickly in order to avoid any drug efllux. Pro- 
tems were then precipitated with 20% trtchloroacetic acid. The acid- 
soluble part was used to evaluate the mtracellular concentration of 
doxorubicm by fluorimetry. using excitation and emission wave- 
lengths of 485 nm and 590 nm, respectively. Prehmmary controls 
showed no toxictty of doxorubictn at the concentration used over the 
mcubation period The results of doxorubicm accumulation studies 
were analysed by Student’s t-test. The criterion of significance of the 
dtfferences between the means (?S.D.) was P < 0 05. 
3. RESULTS 
Hepatocytes were cultured for 9 days after cell seed- 
ing in the absence or presence of DEX (lo-’ M). North- 
ern blotting analysis and hybridization with pCHP1 
DEX 
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Ftg. 2. Western blot analysis of membrane proteins obtained from 
cultured hepatocytes maintamed in the presence or absence of dexam- 
ethasone (DEX). Crude membrane fractions were prepared from 
hepatocytes cultured for 2 days with or without DEX (IO-’ M). 100 
fig membrane protems were separated on SDS-PAGE and transferred 
onto a nitrocellulose sheet. After Incubation with C319 anttbody, the 
blot was developed as described in section 2 Arrows Indicate the 
positton of P-gp. The posttion of molecular size standards (in kDa) is 
indicated on the right. 
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Fig. 3. Intracellular doxorubicm accumulation in hepatocytes cultured 
with or without dexamethasone (DEX). Rat hepatocytes mamtamed 
with or without DEX (lo-’ M) were incubated with 10 pg/ml doxoru- 
bicm for 2 h after 1 and 2 days of culture. The intracellular doxorubi- 
cm concentration was then determined using the fluorimetric method, 
as described in section 2. The values are the mean + S.D of three 
experiments in quintuplicate; *P < 0.05. 
probe revealed high levels of 4.5 kb P-gp mRNA tran- 
scripts in hepatocytes maintained without steroid at day 
1 and especially at day 2 of culture compared to those 
found in freshly isolated hepatocytes (Fig. 1). P-gp 
mRNA levels were also increased in DEX-treated hepa- 
tocytes, but to a much lower extent. Hybridizations with 
mdr 1- and mdr3-specific probes revealed enhanced 
levels of 4.5 kb mdrl mRNA transcripts in cultured 
hepatocytes, particularly in the absence of DEX treat- 
ment, while 5.1 kb mdr3 mRNAs transcripts were not 
detected (Fig. 1). Drug-resistant rat hepatoma cells used 
as positive controls of P-gp expression displayed both 
increased 4.5 kb mdrl and 5.1 kb mdr3 mRNA levels, 
as demonstrated by hybridization with pCHP1 and 
mdr- specific probes. No signal was detected in either 
cultured rat hepatocytes or hepatoma cells using the 
mdd-specific probe (data non shown). 
Crude membranes prepared from cultured rat hepa- 
tocytes maintained in the absence or presence of DEX 
(10m7 M) were used to investigate P-gp expression by 
Western blotting analysis. A C219-reactive band of 140 
kDa corresponding to P-gp was strongly expressed in 
untreated liver cells cultured for 2 days without DEX 
but much weaker in DEX-treated hepatocytes (Fig. 2). 
In order to determine if huge increased P-gp levels in 
DEX-untreated cultures were associated with func- 
tional increased P-gp activity, the cellular accumulation 
of doxorubicin, an anthracycline antitumor drug known 
to be transported by P-gp [l], was measured. As shown 
in Fig. 3, lower intracellular retentions of the anticancer 
compound were found in DEX-untreated hepatocytes 
compared to DEX-treated cells at both day 1 and day 
2 of culture. Addition of verapamil (25 PM), a drug 
known to reverse MDR by inhibiting P-gp function [l], 
led to a significant increase in cellular doxorubicin accu- 
mulation (Fig. 4). Coincubation of doxorubicin with 
various concentrations of DEX for 2 h did not affect 
cellular anthracycline levels in 2-day-old DEX-un- 
treated hepatocytes (Fig. 4). 
The effects of various DEX concentrations on P-gp 
expression in cultured hepatocytes were further charac- 
terized (Fig. 5). Hybridization with pCHP1 probe re- 
vealed increased 4.5 kb mRNAs transcripts in rat liver 
cells maintained in the presence of lo-* M and lower 
concentrations of DEX for 2 days after cell seeding. 
Similarly, expression of the fetal liver marker GST7-7 
[30] was enhanced while expression of albumin, a spe- 
cific marker of adult liver parenchymal cells was con- 
comitantly decreased. By contrast GAPDH mRNAs 
were not affected by DEX treatment whatever the 
hormone concentration used (Fig. 5). 
4. DISCUSSION 
The results reported here show that DEX markedly 
regulates P-gp expression in cultured normal liver cells. 
Northern blot analysis revealed an early and conspi- 
cious increase of P-gp mRNA levels in cultured hepato- 
cytes maintained in the absence of DEX, while DEX- 
treated cells displayed a weaker P-gp induction at the 
studied culture times similar to that previously de- 
scribed [ 171. Similarly, Western blot analysis indicates 
high levels of P-gp in liver cells maintained in the ab- 
sence of DEX. 
Two mdr genes, mdrl and mdr3. have been demon- 
strated to be involved in drug resistance [5]. The use of 
mdr gene-specific probes allowed us to detect in liver 
cell cultures increased levels of mdrl mRNA transcripts 
of 4.5 kb, as previously reported for rat mdrl tran- 
scripts [9]. By contrast, Northern blot hybridizations 
with mdr2- and mdr3-specific probes suggest that both 
- 0 0 0 0 ‘0 ‘0 - 7 
- 7 7 _ 7 
DOX DOX + VR 
DOX + DEX 
Fig. 4. Effect of verapamil (VR) and dexamethasone (DEX) on 
doxorubicm retention in hepatocytes cultured without DEX. Rat 
hepatocytes, mamtained m culture without DEX for 2 days after cell 
seeding. were incubated with 10 /g/ml doxorubicin for 2 h alone or 
with verapamil (25 ,uM) or various concentration of DEX (lO~‘PIO~” 
M). The intracellular doxorubicm concentration was then determined 
using the fluorometric method, as described in section 2. The values 
are the mean f SD. of three experiments m quintuphcate; *P C 0.05. 
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Fig. 5. Expression of P-glycoprotein (P-gp), glutathione-9transferase 
7-7 (GST7-7). albumin (Alb) and glyceraldehyde phosphate dehydro- 
genase (GAPDH) mRNAs in cultured rat hepatocytes exposed to 
various concentrattons of dexamethasone (DEX). Each well contams 
10 pg total RNAs prepared from freshly isolated hepatocytes (FIH) 
or from hepatocytes cultured for 2 days after cell seedmg wrth or 
without vartous concentrattons of DEX (lo-‘-lo-” M) RNAs were 
transferred to Hybond-N sheets after electrophoresis and hybridtzed 
with a P-gp (pCHP1) (A). a GST7-7 (B), an albumin (C) and a 
GAPDH (D) probe. respectively. After hybridizatton, the sheets were 
washed, dried and autoradtographed at -8OOC. Transcript sizes (m 
kb) were estimated relatively to the mrgration of 18 S and 28 S rRNA. 
mdr2 gene, which is not involved in cytotoxic drug 
transport, and mdr3 gene were not strongly induced. 
Consequently it appears that DEX-modulated P-gp in- 
duction in cultured hepatocytes involved mostly, if not 
specifically, mdrl gene. Increased mdrl gene expression 
also occurred in normal liver cells after exposure to 
3-methylcholanthrene or 2-acetyl aminofluorene [3 11. 
Taken together, these data strongly suggest that the 
mdrl gene could play a critical role in P-gp regulation 
in normal rat hepatocytes. This conclusion is moreover 
supported by the recent report demonstrating mdrl 
gene induction in normal rat hepatocytes after protein 
synthesis inhibition through a transcriptional mecha- 
nism [9]. We have also observed a strong induction of 
4.5 mdrl mRNA transcripts in response to cyclo- 
heximide exposure in liver cells maintained in the pres- 
ence or absence of DEX (data non shown), thus suggest- 
ing that DEX treatment does not involve major change 
in P-gp regulation in response to protein synthesis inhi- 
bition. 
The strong induction of P-gp in DEX-untreated 
hepatocytes paralleled a marked decrease in doxorubi- 
tin intracellular retention, thereby indicating that in- 
duced P-gp was functional. This low level of anthracy- 
cline accumulation in DEX-untreated cultures was 
strongly enhanced by the addition of the known P-gp 
modulator agent, verapamil. By contrast, co-incubation 
of doxorubicin and DEX did not affect the cellular drug 
level in 2-day-old hepatocyte cultures previously main- 
tained in the absence of DEX, suggesting thus that DEX 
does not interact with P-gp function. These results also 
favor the idea that DEX is not a substrate for P-gp in 
cultured rat hepatocytes. DEX has already been found 
to be without effect on vinblastine accumulation and 
does not inhibit [3H]vinblastine binding of membrane 
vesicles prepared from murine multidrug-resistant cells. 
in contrast to progesterone [32]. However, similar stud- 
ies performed in human MDRl-transfected cells have 
recently shown that DEX, but not progesterone, is a 
substrate for human P-gp [33]. These conflicting results 
on DEX transport by P-gp could reflect, in fact, differ- 
ences in substrate specificity between human and rodent 
P-gp. 
Analysis of the effects of various DEX concentrations 
demonstrated that maintenance of hepatocyte cultures 
without DEX or with a low DEX concentration, which 
resulted in a strong induction of P-gp, also increased 
expression of the fetal liver marker, GST7-7, and de- 
creased concomitantly the level of albumin. an adult 
liver-specific function. Taken all together. these data 
suggest that modulation of P-gp levels in response to 
DEX treatment could rather be a part of an early and 
marked alteration of differentiation status in untreated 
cultures and cultures exposed to a low DEX concentra- 
tion than a specific action of DEX on mdr 1 gene. A 
relationship between the differentiation status and P-gp 
expression in liver cells is also suggested by high levels 
of mdr mRNAs found in pre-neoplastic and neoplastic 
liver [I l] and by a recent report demonstrating that 
hepatocytes cultured on a reconstituted basement mem- 
brane, termed matrigel, displayed high liver-specific 
functions and reduced P-gp levels, respectively [34]. 
However, it is noteworthy that an induction of P-gp, 
although weak, occurs in DEX-treated cultured hepato- 
cytes. Addition of compounds such as dimethyl sulfox- 
ide and nicotinamide, which favor maintenance of dif- 
ferentiated functions. did not completely abolish the 
P-gp increase in hepatocyte cultures [17]. This could 
thus indicate that other factor(s) not directly related to 
differentiation status, but which could be linked to a 
cellular stress response resulting from cell isolation and 
exposure to an unfamiliar environment, is also involved 
in P-gp induction occurring in cultured rat hepatocytes. 
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In summary, Northern and Western blot analyses 
and P-gp-mediated drug efllux studies have demon- 
strated that DEX modulates P-gp induction in cultured 
rat hepatocytes. This effect of DEX on P-gp involves 
regulation of the mdrl gene; it could be a part of liver 
cell differentiation status modulation by DEX. Further 
studies are needed to clarify if DEX treatment could 
also regulate P-gp expression in drug-resistant tumoral 
cells, that could then lead to a new and interesting use 
of steroid hormones for overcoming MDR in cancers. 
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